A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.

Allakos, Bay Area biotech firm based in San Carlos, is laying off 75% of its staff and eyeing a shutdown after its clinical ...

A Bay Area biotech firm is laying off 75% of its staff following a flopped clinical trial. Allakos, based in San Carlos, ...

Allakos is throwing in the towel. After seeing phase 1 data in hives, the biotech has decided to drop the drug candidate and ...

Allakos, Inc. shares lost more than three-quarters of its market capitalization on Tuesday afternoon, marking a record low ...

In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Hold rating on Allakos (ALLK – Research Report), with a price ...

Allakos said it plans to explore strategic alternatives, adding that it expects its cash, equivalents and investments will total $35 million to $40 million by the end of June. The company now sports a ...

Allakos Inc (ALLK) stock saw a decline, ending the day at $0.24 which represents a decrease of $-0.97 or -80.17% from the prior close of $1.21. The stock opened at $0.3 and touched a low of $0.23 ...

SAN CARLOS, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria ...

It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...

Allakos halts AK006 development after phase 1 trial disappoints. Restructuring includes workforce cuts and $34 million-$38 ...

Jefferies, a global investment banking firm, revised its price target for Allakos Inc . (NASDAQ: NASDAQ:ALLK) shares, ...